Granules India

Granules India (₹795.40) exhibits a conflicting technical structure as of 2026-11-06, characterized by short-term weakness against a longer-term bullish backdrop. On the daily chart, the trend is bearish with price trading below the 20-period and 50-period EMAs and SMAs, while the Supertrend remains negative. Daily ADX at 14.95 indicates weak trend conviction, despite an extreme participation anomaly on the same day where volume was 4.0x normal with no clear directional follow-through. Conversely, the monthly trend remains established and bullish (ADX 29.79), with price above all major moving averages and the Supertrend. The stock sits in the upper-middle of its 252-day range (+67.4%) but near the lower end of its 50-day range (+20.9%). A weekly Harami pattern has formed, suggesting potential consolidation or reversal after recent declines. Key resistance lies at ₹796.78 (pivot) and ₹806.09, while immediate support is at ₹791.00. Annualized volatility stands at +32.2%, with a current drawdown of -12.5% from highs.

Granules India reported Q2FY27 results after market hours on Monday, November 3, 2026, showing a 39% jump in profit. Despite the profit growth, revenue growth was steady rather than accelerated, and margins softened due to slowing performance in its US formulations business. Following these results, Emkay Global Financial issued a 'Buy' recommendation with a price target of ₹950 on November 3, 2026. The stock also participated in a broader market advance driven by strong corporate earnings and easing crude oil prices.

On November 6, 2026, Granules India filed the transcript of its Q2 and H1 FY27 earnings conference call with the NSE, marking a significant update to its financial and operational profile. The company reported record quarterly revenue of ₹15,600 million (up 20% YoY) and PAT of ₹1,818 million (up 39% YoY), driven by broad-based growth in North America and Europe. A key structural change is the transition to a net cash position of ₹8,280 million following warrant proceeds. However, gross margins compressed to 64.4% due to higher input and logistics costs linked to West Asia conflicts. Regulatory developments include an FDA Form 483 with eleven observations at the Gagillapur facility (none related to data integrity or cross-contamination) and a successful Swiss Medic GMP inspection for Senn Tides’ Zurich site. Strategically, management outlined a shift toward complex generics and first-to-file ANDAs, with five new product launches planned for Q3/Q4 and a projected ₹2,000 crore capex program over three to four years focused on peptide CDMO capacity in Zurich and Vizag. Additionally, KFin Technologies Limited notified the exchange of a corporate office address change effective December 1, 2026.

Granules India Limited reported record Q2 FY27 financials, with revenue rising 20% year-over-year to ₹15,600 million and PAT increasing 39% to ₹1,818 million. A significant capital structure shift occurred as the company converted warrants into equity shares worth ₹10,961.25 million, transitioning from a net debt position of ₹1,012 million in Q1 to a net cash balance of ₹8,280 million by quarter-end. Regulatory developments include eleven observations from a USFDA inspection at the Gagillapur facility; management stated these do not involve data integrity or cross-contamination and have no impact on manufacturing. Additionally, two new wholly-owned subsidiaries were incorporated in Brazil and Mexico to support international expansion.

Granules India demonstrates a robust operational expansion in Q2 FY2026-27, with revenue from operations rising sequentially to ₹1,560 crore and net profit increasing to ₹182 crore. This follows a strong annual trajectory where TTM sales reached ₹5,895 crore and TTM net profit grew to ₹714 crore, supported by a TTM compounded profit growth rate of 37%. The balance sheet reflects significant capacity building, with Property, Plant, and Equipment (PPE) expanding to ₹3,403 crore as of September 2026, up from ₹2,612 crore a year prior. Cash generation remains healthy, with Cash from Operating Activity at ₹793 crore for the fiscal year ended March 2026, although the Cash Conversion Cycle lengthened to 256 days due to higher inventory levels.

A notable divergence exists between top-line strength and per-share metrics: while absolute net profit rose, Basic EPS decreased slightly to ₹7.22 in Q2 FY2026-27 from ₹7.26 in Q1, likely reflecting the dilutive impact of increased equity capital (rising to ₹27 crore by Sep 2026). Interest costs remained controlled at ₹21 crore in Q2, down marginally from Q1, despite total borrowings decreasing to ₹1,101 crore by September 2026. The company’s ROCE improved to 16% in March 2026, indicating efficient utilization of expanded assets.

Granules India presents a conditional upside case anchored by strong recent profitability and divergent technical momentum across timeframes. The company reported a 39% jump in profit for the second quarter (ended September), signaling robust operational execution despite noted margin softening in its US formulations business. This fundamental strength is reflected in a +44.0% one-year return and a +28.5% year-to-date gain, outperforming shorter-term trends where the stock has seen -5.2% over three months and -4.9% over one month.

Technically, the monthly trend remains bullish with an ADX of 29.79 and a positive directional indicator (PLUS_DI: 25.82), suggesting underlying medium-term strength. However, the daily trend is bearish (ADX: 14.95, MINUS_DI: 25.04), indicating near-term volatility and selling pressure. The stock closed at ₹795.4 on November 6, 2026, trading within a narrow range between support at ₹791.0 and resistance at ₹796.78. A constructive interpretation depends on the stock stabilizing above key daily supports while the monthly bullish structure holds, potentially allowing the near-term weakness to resolve into a continuation of the longer-term upward trajectory.

Granules India faces near-term operational headwinds despite strong profit growth, primarily driven by margin softening in its US formulations business during the September quarter. This structural pressure contrasts with the reported 39% jump in Q2 profit, suggesting that top-line stability may not fully offset cost or pricing challenges in key markets. Technically, the stock is trading in a bearish daily trend, with the Supertrend indicator signaling downside momentum and the 20-day moving average slope remaining negative (-6.65). The share price has retreated -4.9% over the last month and is currently -12.5% below its recent peak, indicating sustained selling pressure. While the monthly trend remains bullish, the divergence between short-term technical weakness and longer-term strength highlights elevated volatility (annualized at +32.2%) and a potential risk of further consolidation if support levels fail to hold.